The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Investigation of the pharmacogenetic influences of carbonyl reductase on doxorubicin and doxorubicinol in breast cancer patients.
Allison Gaudy
No relevant relationships to disclose
Gerald J. Fetterly
No relevant relationships to disclose
Alex A. Adjei
No relevant relationships to disclose
Tracey L. O'Connor
No relevant relationships to disclose
Adolfo Quinones
No relevant relationships to disclose
Javier G. Blanco
No relevant relationships to disclose
Daniel Ferguson
No relevant relationships to disclose
Patricia D. Meholick
No relevant relationships to disclose
James Kalabus
No relevant relationships to disclose